BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28459463)

  • 1. MYCN induces neuroblastoma in primary neural crest cells.
    Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
    Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations.
    Saldana-Guerrero IM; Montano-Gutierrez LF; Boswell K; Hafemeister C; Poon E; Shaw LE; Stavish D; Lea RA; Wernig-Zorc S; Bozsaky E; Fetahu IS; Zoescher P; Pötschger U; Bernkopf M; Wenninger-Weinzierl A; Sturtzel C; Souilhol C; Tarelli S; Shoeb MR; Bozatzi P; Rados M; Guarini M; Buri MC; Weninger W; Putz EM; Huang M; Ladenstein R; Andrews PW; Barbaric I; Cresswell GD; Bryant HE; Distel M; Chesler L; Taschner-Mandl S; Farlik M; Tsakiridis A; Halbritter F
    Nat Commun; 2024 May; 15(1):3745. PubMed ID: 38702304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations.
    Dabkowski TR; Varkhedi M; Song JJ; Gozlan EC; Blanck G
    JCO Precis Oncol; 2023 Sep; 7():e2300057. PubMed ID: 38085056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.
    Oskouian B; Lee JY; Asgharzadeh S; Khan R; Zhang M; Weisbrod JR; Choi YJ; Puri L; Aguilar AE; Zhao P; Saba JD
    Oncogene; 2024 Apr; 43(16):1203-1213. PubMed ID: 38413795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
    Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
    Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroblastoma progress on many fronts: the Neuroblastoma Research Symposium.
    Wylie L; Philpott A
    Pediatr Blood Cancer; 2012 Apr; 58(4):649-51. PubMed ID: 21922652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.
    Teitz T; Inoue M; Valentine MB; Zhu K; Rehg JE; Zhao W; Finkelstein D; Wang YD; Johnson MD; Calabrese C; Rubinstein M; Hakem R; Weiss WA; Lahti JM
    Cancer Res; 2013 Jul; 73(13):4086-97. PubMed ID: 23536557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.
    Dvorkina M; Nieddu V; Chakelam S; Pezzolo A; Cantilena S; Leite AP; Chayka O; Regad T; Pistorio A; Sementa AR; Virasami A; Barton J; Montano X; Lechertier T; Brindle N; Morgenstern D; Lebras M; Burns AJ; Saunders NJ; Hodivala-Dilke K; Bagella L; De The H; Anderson J; Sebire N; Pistoia V; Sala A; Salomoni P
    Clin Cancer Res; 2016 Jul; 22(13):3398-409. PubMed ID: 27076624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic structural variation targets neurodevelopmental genes and identifies
    Lopez G; Conkrite KL; Doepner M; Rathi KS; Modi A; Vaksman Z; Farra LM; Hyson E; Noureddine M; Wei JS; Smith MA; Asgharzadeh S; Seeger RC; Khan J; Auvil JG; Gerhard DS; Maris JM; Diskin SJ
    Genome Res; 2020 Sep; 30(9):1228-1242. PubMed ID: 32796005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroblastoma Patients' Outcome and Chromosomal Instability.
    Ognibene M; De Marco P; Amoroso L; Fragola M; Zara F; Parodi S; Pezzolo A
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures.
    Schoof M; Godbole S; Albert TK; Dottermusch M; Walter C; Ballast A; Qin N; Olivera MB; Göbel C; Neyazi S; Holdhof D; Kresbach C; Peter LS; Epplen GD; Thaden V; Spohn M; Blattner-Johnson M; Modemann F; Mynarek M; Rutkowski S; Sill M; Varghese J; Afflerbach AK; Eckhardt A; Münter D; Verma A; Struve N; Jones DTW; Remke M; Neumann JE; Kerl K; Schüller U
    Nat Commun; 2023 Nov; 14(1):7717. PubMed ID: 38001143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WNT signaling, the development of the sympathoadrenal-paraganglionic system and neuroblastoma.
    Becker J; Wilting J
    Cell Mol Life Sci; 2018 Mar; 75(6):1057-1070. PubMed ID: 29058015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Id2 Protein in Neuroblatoma in Children.
    Wieczorek A; Balwierz W
    Pathol Oncol Res; 2015 Sep; 21(4):999-1004. PubMed ID: 25771836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
    Walton JD; Kattan DR; Thomas SK; Spengler BA; Guo HF; Biedler JL; Cheung NK; Ross RA
    Neoplasia; 2004; 6(6):838-45. PubMed ID: 15720811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell atlas of developing murine adrenal gland reveals relation of Schwann cell precursor signature to neuroblastoma phenotype.
    Hanemaaijer ES; Margaritis T; Sanders K; Bos FL; Candelli T; Al-Saati H; van Noesel MM; Meyer-Wentrup FAG; van de Wetering M; Holstege FCP; Clevers H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33500353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuroblastoma-like schwannoma of the lung: report of a case].
    Hua HJ; Li KD; Zhu Y; Fan QH; Li H
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):492-494. PubMed ID: 38678334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma.
    Onyeukwu C; Williams A; Seyboth B; Muñoz L; Scaria G; Kent P
    J Pediatr Hematol Oncol; 2024 Mar; 46(2):e188-e190. PubMed ID: 38189408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell.
    Kildisiute G; Kholosy WM; Young MD; Roberts K; Elmentaite R; van Hooff SR; Pacyna CN; Khabirova E; Piapi A; Thevanesan C; Bugallo-Blanco E; Burke C; Mamanova L; Keller KM; Langenberg-Ververgaert KPS; Lijnzaad P; Margaritis T; Holstege FCP; Tas ML; Wijnen MHWA; van Noesel MM; Del Valle I; Barone G; van der Linden R; Duncan C; Anderson J; Achermann JC; Haniffa M; Teichmann SA; Rampling D; Sebire NJ; He X; de Krijger RR; Barker RA; Meyer KB; Bayraktar O; Straathof K; Molenaar JJ; Behjati S
    Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival following complete resection of neuroblastoma in novel orthotopic rat xenograft model.
    Sever RE; Rosenblum LT; Reyes-Múgica M; Edwards WB; Malek MM; Kohanbash G
    Sci Rep; 2023 Nov; 13(1):20214. PubMed ID: 37980388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.